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Background: The 5 G/5 G genotype of PAI-1 polymorphism is linked to decreased plasminogen activator inhibitor-1
(PAI-1) levels and it has been suggested that lower PAI-1 levels may provide protective effects on inflammation, local
microcirculatory disturbance, and fibrotic changes, which are likely associated with development of sudden sensorineural
hearing loss (SSNHL).
Methods: The association of the 4 G/5 G PAI-1 polymorphism with the development and clinical outcome of SSNHL is
evaluated via a case control study. 103 patients with SSNHL and 113 age and sex-matched controls were enrolled at
University of Ferrara, Italy and hearing loss outcome was measured at least 3 months after the onset of hearing loss.
DNA was isolated from peripheral blood using the QIAamp kit and the 4 G/5 G polymorphism in the −675 promoter
region was genotyped with an allele-specific PCR. Genotype distribution was tested in patients and compared to
controls by chi-square and odd-ratio analysis. The codominant and recessive models were used for the multiple logistic
regression analyses of the PAI-1 gene allele.
Results: In this population, 5 G/5 G genotype had a two-time lower frequency in SSNHL patients compared to healthy
controls (15.5% vs 30.1%) and was associated with decreased odds compared to 4 G/5 G genotype (OR 0.37, 95% CI 0.19-
0.75, p=0.005). In addition, the patients with 5 G/5 G genotype showed a trend of more than 2 times higher ratio of
hearing recovery (> 20 dB) after systemic corticosteroid treatment compared to 4 G/5 G genotype (OR 2.3, 95% CI 0.32 -
16.83, p=0.39), suggesting a better clinical outcome.
Conclusions: The 5 G/5 G genotype of PAI-1 may be associated with a reduced risk of SSNHL in the Italian population.
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Sudden sensorineural hearing loss (SSNHL) is defined as a
rapid onset sensorineural hearing loss occurring over a
72-hour period with a decrease in hearing of> 30 decibels
(dB) affecting at least 3 consecutive frequencies [1]. The
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reproduction in any medium, provided the orcauses and are thus classified as “idiopathic” [2]. SSNHL
affects 5 to 20 persons for each 100,000 individuals annu-
ally and can be devastating because they can lose their
hearing permanently. The etiology of SSNHL is still un-
clear although the most recent studies suggest viral infec-
tion, vascular impairment, intracochlear membrane
rupture, and autoimmune process as possible causes [3,4].
Several studies have been reported on the association be-
tween cardiovascular risk factors and SSNHL, showing
that high concentrations of cholesterol, fibrinogen, and
homocysteine were risk factors [5-9]. Other reports evalu-
ated the association between SSNHL and genetic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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V Leiden and prothrombin G20210A variant, with contro-
versial results [10-13].
Plasminogen activator inhibitor-1 (PAI-1) is the princi-
pal inhibitor of tissue plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA), which
actively facilitate plasminogen, and hence fibrinolysis.
PAI-1 is a key molecule for thrombus formation and
inflammation [14]. Elevation in plasma levels of PAI-1
has been reported to be associated with many diseases,
such as cardiovascular diseases [14], stroke [15] and
asthma [16-18]. Marcucci et al. [6] also reported that
plasma levels of PAI-1 were significantly higher in
patients with SSNHL compared to control subjects. One
of most probable causes of SSNHL appears to be
impaired cochlear blood circulation involving the patho-
genic micro-thrombotic mechanism [19,20]. Cochlear
function is very sensitive to changes in blood supply
which is mainly derived from the labyrinthine artery.
Vascular compromise of the cochlea caused by reduced
blood flow, vasospasm, thrombosis or embolus, may re-
sult in SSNHL [13,21]. Our previous case report demon-
strated the effectiveness of fibrinolytic therapy for
sudden hearing loss with an improvement of 50 dB using
a recombinant tPA, which appeared to improve the
microcirculation of the inner ear [20]. These findings
suggest that PAI-1 is a possible risk factor and a poten-
tial therapeutic target for SSNHL.
The PAI-1 gene has variation in the promoter region
on the basis of a single guanosine insertion-deletion
(5 G or 4 G) [16]. Previous studies on healthy subjects
show the PAI-1 genotype distribution of 4G4G, 4G5G
and 5G5G were 36.4%, 50.5% and 12.9% for a German
population [11], 27.4%, 47.0%, and 25.6% for an Italian
population [22], 28.7%, 42.5%, and 28.7% for a Turkish
population [19], and 27.5%, 52.5% and 20.0% for a Span-
ish population [23] respectively. It has been reported
that the subjects with 4 G/4 G have increased plasma
PAI-1 levels and the ones with 5 G/5 G have decreased
plasma levels, while the ones with 4 G/5 G have inter-
mediate plasma levels [24]. Increased PAI-1 levels facili-
tate the inhibition of the fibrinolytic system [16], which
may impair cochlear blood circulation and thus predis-
pose the development of SSNHL [6,20]. It has been
reported that the 4 G/5 G polymorphism of PAI-1 gene
is associated with cardiovascular and thromboembolic
diseases [16,25]. Rudack, Yildiz, and their coworkers also
investigated the association between PAI-1 4 G/5 G
polymorphism and SSHNL in the German [11] and
Turkish [19] populations although the results were not
conclusive.
In this study we investigated the 4 G/5 G polymor-
phism of PAI-1 gene in the Italian patients with SSNHL
to see if this polymorphism is a risk factor in developingSSNHL and can be used as a prognostic indicator for
clinical outcome in patients with this disease. We
demonstrated a significant contribution of 5 G/5 G poly-
morphism to lowering the risk of developing SSNHL
and a trend of improved hearing recovery in follow up
evaluation after treatment of SSNHL.
Methods
Patients and controls
One hundred and three patients, 54 females and 49
males (age range, 23–83; female mean age 54.1, male
mean age 55.7), were evaluated at the Department of
Audiology at the University of Ferrara and Modena with
a diagnosis of SSNHL and gave their consent to partici-
pate in the study. They were referred to the department
from January 2005 to December 2009. All the patients
underwent audiological examinations including pure
tone audiometry, speech recognition threshold, immit-
tance measurements such as tympanogram and acoustic
reflex; other audiometric tests for the differential diagno-
sis of cochlear vs retrocochlear pathologies were per-
formed in selected cases. Auditory brainstem response
(ABR) was always performed except when hearing loss
exceeded 80 dB in the acute frequencies. Audiometric
inclusion criterion was a decrease in hearing of at least
30 dB in 3 contiguous frequencies. The following scale
of hearing loss degree was used: mild, ≥ 30 to< 40 dB
hearing loss; moderate, ≥ 40 to< 70 dB hearing loss; se-
vere, ≥ 70 to< 90 dB hearing loss; and profound, ≥
90 dB hearing loss. Patients did not receive vestibular
evaluation because exclusion criteria were the presence
of vertigo or suspected Meniere’s disease. Acoustic neur-
oma was excluded by performing MRI or by serial audi-
ometry in selected cases. Any participant with a history
of head trauma was also excluded from the study.
All the subjects provided their informed consent for
the study and blood was taken as usual for routine la-
boratory exams, in the morning before starting the
pharmacological therapy. Medical treatment consisted of
betamethasone 4 mg i.m. for 3 days and 1.5 mg i.m. for
3–4 days, and oral prednisone was administered for at
least 7 days afterwards, depending on clinical evolution.
Pure tone audiometry was repeated daily according the
history of the patient. We examined follow-up audiom-
etry at least 6 months after the initial episode of hearing
loss and considered a hearing improvement more than
20 dB as a significant recovery. The practice guidelines
suggest <10 dB changes as no recovery [2]. Therefore
we chose 20 dB as a clear cut-off for significant improve-
ment, which would include partial and complete recov-
ery. The age and sex-matched healthy Italian subjects
(n = 113) were enrolled in the same geographical area.
Control subjects had no history of hearing loss, circulatory
or metabolic diseases, or autoimmune disorders. They
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otolaryngology disorders, such as allergic rhinitis, who
gave their consent for the study. All of them had normal
hearing.
DNA extraction
Blood was taken from each patient or control for gen-
omic DNA extraction, which was performed using the
QIAamp kit (Qiagen Inc., Valencia, CA) as directed to
obtain 3 to 12 μg of DNA from 200 μl whole blood.
PAI-1 genotyping
The PAI-1 4 G/5 G genotype was analyzed with an
allele-specific PCR modified from that of Falk et al. [26],
using an alternative forward primer (GTCTGGA
CACGTGGGGG for the 5 G allele or GTCTGGA
CACGTGGGGA for the 4 G allele) with a common
reverse primer (TGCAGCCAGCCACGTGATTGTC
TAG, designed to minimize primer-dimer formation)
and a control reverse upstream primer (AAGCTTT
TACC ATGGTAACCCCTGGT). The PCR procedure
included a hot-start initial step to avoid primer-dimer
artifacts. The PCR mixture was subjected to 30-step
cycles of 94°C (1 minute), 60°C (1 minute) and 72°C (1
minute). The PCR reaction was performed in a total vol-
ume of 25 μl with 0.5 μg of genomic DNA by using
C1000TM Thermal Cycler (Bio-Rad Laboratories, Inc.,
Hercules, CA). The reaction mixture contained
10 mmol/L Tris–HCl (pH 8.0), 2.5 mmol/L MgCl2,
200 μmol/L deoxyribonucleoside triphosphates, and 25
pmol of each primer. For each PCR, 2.5 U of Taq poly-
merase (Promega, Madison, MI) was used. Electrophor-
esis was performed in 2% agarose with 1 x TAE buffer.
The gels were photographed after ethidium bromide
staining. As a control of this PCR technique, PCR ana-
lysis was performed on DNA samples of known
genotypes.
Statistical analysis
Genotype distribution and allele frequencies were tested
in patients and compared to controls by chi-square testFigure 1 Gel patterns demonstrating the 4 G and 5 G alleles in the pr
primer for the 4 G allele or the 5 G allele and a control upstream primer ar
(4 G/5 G genotype); Lanes 3 and 4 for patient B (4 G/4 G genotype); and L(χ2) and odd-ratio analysis using GraphPad Prism for
Windows version 4.03 (GraphPad Software Inc., San
Diego, CA). We also used chi-square test (χ2) and odd-
ratio analysis for the association between genotype dis-
tribution and hearing outcome. A p value of less than
0.05 was considered to be statistically significant. All
odds ratios (OR) are given with their 95% confidence
interval (CI). In the multiple logistic regression analyses
for each PAI-1 gene allele, we used multiple inheritance
models, including codominant model (the relative haz-
ard differed between subjects with one minor allele and
those with two minor alleles) and recessive model (only
subjects with two minor alleles were at increased risk of
the disease). 5 G was considered the minor allele in our
case.
Results
A total of 103 SSNHL patients and 113 healthy controls
were analyzed for 4 G and 5 G PAI-1 gene alleles. A typ-
ical PAI-1 genotyping experiment is shown in Figure 1.
The frequencies of allele 4 G were 48.7% in SSNHL and
47.1% in controls, comparable to those for allele 5 G of
51.3% (SSNHL) and 52.9% (controls). The frequencies of
genotypes 4 G/5 G, 4 G/4 G, and 5 G/5 G were 61.2%,
23.3%, and 15.5%, respectively, in SSNHL, and 44.2%,
25.7%, and 30.1% in controls (Table 1). The prevalence
of 5 G/5 G genotype in the SSNHL patients (15.5%) was
two times lower than that in control (30.1%). The 5 G/
5 G genotype appeared to have the risk effect three
times lower than that of the 4 G/5 G genotype (OR 0.37,
95% CI 0.19-0.75, p< 0.005), which is the most prevalent
genotype. When we compared the 5 G/5 G genotype
with combined non-5 G/5 G genotypes (4 G/5 G+ 4 G/
4 G), the 5 G/5 G genotype had two times lower risk of
developing SSNHL than non-5 G/5 G genotypes. How-
ever, the 4 G/4 G genotype did not have significantly
increased risk compared to the 4 G/5 G genotype.
We further examined to see if the polymorphism of
PAI-1 gene is associated with clinical outcome in
patients with SSNHL (Table 2). We were able to obtain
follow-up pure tone audiometry from only 34 patients.omoter region of the PAI-1 gene. PCR products with a forward
e indicated by 4 G or 5 G, respectively; Lanes 1 and 2 for patient A
anes 5 and 6 for patient C (5 G/5 G genotype).
Table 1 Genotype distribution of PAI-1 polymorphism in SSNHL and controls
Model Genotype Controls, n = 113
(Frequency)
SSNHL, n = 103
(Frequency)
OR 95 % CI χ2 p value
Co-dominant 4 G/5 G 50 (44.2 %) 63 (61.2 %) 1
4 G/4 G 29 (25.7 %) 24 (23.3 %) 0.66 0.34 – 1.27 1.59 0.210
5 G/5 G 34 (30.1 %) 16 (15.5 %) 0.37 0.19 - 0.75 7.83 0.005
Recessive 4 G/4 G-4 G/5 G 79 (69.9 %) 87 (84.5 %) 1
5 G/5 G 34 (30.1 %) 16 (15.5 %) 0.43 0.22 - 0.83 6.42 0.011
SSNHL sudden sensorineural hearing loss; Odds ratios (OR) with 95 % confidence intervals (CI) and results (p values) of χ2 analysis (chi-square test) were calculated
for genotype frequencies compared with control.
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and bilateral in 1. Among the unilateral cases, the degree
of SSNHL was mild in 6 patients, moderate in 15, severe
in 8, and profound in 4; one bilateral case was moderate
degree in both side. Among these SSNHL patients,
patients with 5 G/5 G genotype showed a tendency to
have better outcome with 60% of patients having> 20 dB
recovery after treatment, while patients with 4 G/5 G
and 4 G/4 G genotypes had only 39.1% and 33.3% recov-
ery rates (> 20 dB improvement), respectively. The
genotype 5 G/5 G appeared to have a recovery effect 2.3
times higher than that of 4 G/5 G (OR 2.33; 95% CI 0.32
- 16.83). However, this finding of better clinical outcome
in patients with the 5 G/5 G genotype was not statisti-
cally significant due to a relatively small number of
patients who had received the available follow-up pure
tone audiometry.Discussion
One of most probable mechanisms of SSNHL appears to
be impaired cochlear blood circulation involving the
pathogenic micro-thrombotic mechanism [20]. There are
precedent polymorphism studies on the roles of various
prothrombotic risk factors in SSNHL, including GPIa
C807T [27], FV 1691 G-A [11,28], MTHFR 677 C-T
[12,19], and G20210A [10,29]. It has been known that
elevated plasma levels of PAI-1 are associated with
SSNHL [6], but the role of the PAI-1 is controversial
[6,11]. In this study, we found that the 5 G/5 G genotype
of the PAI-1 gene was associated with reduced risk of
developing SSNHL.Table 2 Significant hearing improvement (> 20 dB) in
PAI-1 polymorphism
Genotype 4 G/5 G, n = 23
(Frequency)
5 G/5 G, n = 5
(Frequency)
4 G/4 G, n = 6
(Frequency)
No improvement 14 (60.9%) 2 (40.0%) 4 (66.7%)
Improvement 9 (39.1%) 3 (60.0%) 2 (33.3%)
OR (95% CI) 1 2.33 (0.32 - 16.83) 0.78 (0.12 - 5.17)
χ2; p value 0.73; 0.39 0.068; 0.79
OR odd ratio, CI confidence interval.To investigate the potential contribution of poly-
morphism within the PAI-1 gene to the development of
SSNHL, we recruited SSNHL patients and control sub-
jects from Ferrara and Modena, Italy, from a white,
homogeneous population. In this population, we found
the frequencies of 5 G allele (51.3%, 52.9%) had no sig-
nificant difference from those of 4 G allele (48.7%,
47.1%) either in patients or in controls. However, the fre-
quency of the 5 G/5 G genotype was two times lower in
the SSNHL group (15.5%) compared to that in the con-
trol group (30.2%). This 5 G/5 G genotype showed 2–3
times lower risk effect than 4 G/4 G and 4 G/5 G. In this
study, we found the 4 G/4 G genotype had no significant
risk ratio in developing SSNHL. However, the 5 G/5 G
genotype appeared to have a protective effect against
developing SSNHL. Our findings are supported by sev-
eral previous reports that the patients with 5 G/5 G
genotype are known to have lower plasma levels of PAI-1
compared to those with 4 G/4 G [16,24], and lower PAI-1
level can provide protective effects on inflammation, local
microcirculatory disturbance, and fibrotic changes, which
are likely associated with developing SSNHL [4,6,30]. Our
data showing the significance of the 5 G/5 G genotype are
different from a previous study on German patients with
SSNHL [11], where the 5 G/5 G genotype in the experi-
mental group had no significant difference in frequency
compared to the controls. Notably, their study showed the
control genotype distribution were 36.4% (4G4G), 50.5%
(4G5G), and 12.9% (5G5G), significantly different from
our control study with Italian population (25.7%, 44.2%,
and 30.1%). Additionally, their study elected only severe
SSNHL patients with a loss of 60 dB or more. In contrast,
our study recruited patients with a hearing loss of 30 dB
or more. It is not clear whether the discrepancy between
these two studies is due to different population (Italian vs
German) or different severity of the disease.
It has been known that there is no effective treatment of
SSNHL other than systemic corticosteroids which is gen-
erally used but has limitation to some patients [2]. Our
study suggests that lowering plasma levels of PAI-1 may
be a strategy to prevent SSNHL, especially in people who
are likely to have high plasma levels of PAI-1, such as
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study also suggests that the patients with the 5 G/5 G
genotype have a tendency of 2–3 times higher ratio of
hearing recovery (> 20 dB) compared to those with the
4 G/4 G and 4 G/5 G genotypes, although it was not sta-
tistically significant. We defined a change in hearing of
> 20 dB as significant improvement, although practice
guidelines usually suggest >10 dB improvement as signifi-
cant, which includes both partial and complete recovery.
We had a limited number of long-term follow-up audiom-
etry results, which resulted in a lack of power in our ana-
lysis. Collecting more data on long-term follow-up
audiometry would provide better insight into the influence
of 4 G/5 G genotype on the clinical outcomes of SSNHL.
We previously reported a case which showed significant
improvement of hearing (> 50 dB) with recombinant tPA
treatment two years after the development of SSNHL [20].
This case is an interesting observation that may suggest a
link between fibrinolytic treatment and clinical outcome
in patients with SSNHL. However, it is too early to suggest
tPA use as an alternative treatment for SSNHL.
Conclusions
This study suggests that the individuals with the 5 G/5 G
genotype of PAI-1 have less risk of developing SSNHL,
and the 5 G/5 G genotype may function as a prognostic
factor in recovery from SSNHL. This result may be of
clinical significance in diagnosis, treatment, and prognosis
for SSNHL patients and may provide a new therapeutic
strategy for SSNHL.
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